HMS Virology

Virology Faculty Member - Dan Barouch

Dan Barouch

William Bosworth Castle Professor of Medicine

Beth Israel Deaconess Med Ctr
Viral Pathogenesis Div - E/CLS - 1047
330 Brookline Ave
Boston, MA 02215
Tel: 617-735-4485
Fax: 617-735-4527
Lab Members: 8 postdocs, 2 predocs
Visit my lab page here.

My laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine strategies. We have demonstrated that cellular immune responses can partially control viral replication, but that the virus can readily escape from immune control. In particular, we have shown that adjuvanted DNA vaccines and viral vector-based vaccines expressing SIV antigens can elicit potent cellular immune responses that partially control pathogenic virus challenges in rhesus monkeys. These results suggest that HIV-1 vaccines that generate potent cellular immune responses may provide important benefits even if they fail to afford sterilizing immunity. We have also developed a series of rare serotype and chimeric adenovirus vector-based vaccines that overcome the critical problem of pre-existing immunity to the common adenovirus serotype 5 (Ad5) vector in the developing world. We have identified optimal rare serotype and chimeric adenovirus vectors, and we have advanced these vectors into preclinical studies and phase 1 clinical trials. My laboratory is also a key part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVD), the NIH Center for HIV/AIDS Vaccine Immunology (CHAVI), and the Ragon Institute of MGH, MIT, and Harvard.

Last Update: 8/10/2020


For a complete listing of publications click here.



Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, CE, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-492.

Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC, Lewis MG, Wolinsky SM, Letvin NL. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415:335-339.

Roberts DR, Nanda A, Havenga MJE, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AAC, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006; 441:239-243.
Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008; 455:613-619.

Liu J, O’Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009; 457:87-91.

Barouch DH, Korber B. HIV-1 vaccine development after STEP. Annu. Rev. Med. 2009; in press.

O’Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, Hutnick NA, Betts MR, Dubey SA, Goudsmit J, Shiver JW, Robertson MN, Casimiro DR, Barouch DH. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat. Med. 2009; in press.

© 2016 President and Fellows
of Harvard College